Foamix Pharmaceuticals (FOMX) stock has fallen -56.97% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives FOMX stock a score of 47 out of a possible 100.
That score is primarily influenced by a long-term technical score of 20. FOMX’s score also includes a short-term technical score of 33. The fundamental score for FOMX is 89. In addition to the average rating from Wall Street analysts, FOMX stock has a mean target price of $15.60. This means analysts expect the stock to climb 531.58% over the next 12 months.
What’s Happening with FOMX Stock Today
Foamix Pharmaceuticals Ltd (FOMX) stock has risen 15.42% while the S&P 500 has fallen -0.35% as of 10:38 AM on Tuesday, Jul 30. FOMX is up $0.33 from the previous closing price of $2.14 on volume of 2,814,703 shares. Over the past year the S&P 500 is up 7.41% while FOMX has fallen -56.97%. FOMX lost -$1.70 per share in the over the last 12 months.